Pipeline

Five Prime is pursuing discovery and clinical development of its product candidates both independently and in collaboration with pharmaceutical partners. This approach has been successful – to date, we have received more than $305 million under collaboration arrangements, with potential for additional milestone and royalty payments – and it has allowed us to bolster the capital resources needed to build our drug discovery platform while also expanding our pipeline of product candidates.

We are currently focused on therapies for cancer and inflammatory diseases for our own pipeline. Three drug candidates in these areas have progressed into active or imminent human clinical trials.  We are also focusing our earlier stage research efforts on cancer immunotherapy.

Product
Indication
Research
Preclinical
Phase 1
Phase 1b
Phase 2
FPA008
CSF1R Antibody
Rheumatoid Arthritis
     
FPA008
CSF1R Antibody
6 cancers in combination with nivolumab
     
FPA144
FGFR2b Antibody
Gastric Cancer
     
FP-1039
FGF Ligand Trap
Squamous NSCLC
     
FP-1039
FGF Ligand Trap
Mesothelioma